Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Survey Shows One In Five Patients With Parkinson’s Disease And Troublesome Symptoms Should Be ...

13.12.2007
... Considered For Deep-Brain Stimulation

Findings from a new observational survey show that around one in five patients with troublesome symptoms related to Parkinson's disease may benefit from deep-brain stimulation (DBS) and should be considered for the treatment.1

The survey was conducted in four European countries (Belgium, Germany, Italy, Spain) and Canada with the support of a new screening program, STIMULUS, that has the potential to help neurologists identify patients who could benefit from DBS. The results were presented today at the 17th World Congress on Parkinson’s disease and Related Disorders (WCPD) in Amsterdam.(1)

“Deep-brain stimulation has been proven to be a very effective solution for certain patients with Parkinson’s disease, who have not achieved an acceptable level of control over their motor symptoms with medication alone” stated Doctor Jan Herzog, Department of Neurology, Christian-Albrechts-Universität in Kiel, Germany and member of the expert panel that developed the STIMULUS program.

“However, the complexity of Parkinson’s disease makes it very challenging for general neurologists to identify the appropriate candidates for DBS. Good patient selection is critical to get the most effective results with deep-brain stimulation” added Doctor Herzog.

There are over one million patients with Parkinson’s disease in Europe.(2) However, a large number of patients who could benefit from DBS are never referred, and as many as 63 percent of those who are referred disappointingly find out that they are not eligible for the procedure.(3)

Currently patients receive DBS treatment on average 14 years after the diagnosis of Parkinson’s disease.(4) At that stage, the severity of the disease has already significantly impaired social and professional activities. The data presented today show that this patient screening program can assist general neurologists in identifying patients to be referred for evaluation for DBS before the disease progression limits the potential benefits. With accurate patient and referral to specialist centres over 100,000 patients with Parkinson’s disease in Europe could be considered for DBS treatment, which may help get their symptoms under control and significantly improve their quality of life.(2) (5)

DBS in Parkinson’s Disease
The benefits of DBS have been shown in clinical trials in patients with Parkinson’s disease. Results from a randomised trial show that DBS combined with medication significantly improves quality of life compared to conventional medical treatment alone.(6) Additionally, DBS has been shown to improve motor symptoms substantially and maintain overall function for at least five years in patients with advanced Parkinson’s disease.(7) A recent literature review shows that DBS is the most efficacious treatment for improving quality of life in patients with Parkinson’s disease.(8)

“Deep-brain stimulation is a treatment that has been shown to improve both motor function and quality of life in patients with Parkinson’s disease” said Stephen Pickard, President of the European Parkinson’s Disease Awareness (EPDA). “Enabling people to regain control of their body and undertake tasks with increased independence not only improves their physical well-being but also greatly improves the emotional health of both the person with Parkinson’s and their family/carers.”

STIMULUS Survey Results
The survey presented at WCPD was conducted among 106 neurologists in Belgium, Germany, Italy, Spain and Canada, who screened 1,530 patients with the help of the STIMULUS program.(1) This is a computer-based patient screening program developed by an independent international panel of 12 movement disorders experts, (including Doctor Herzog) who identified five absolute criteria that a patient with Parkinson’s disease must meet, plus an additional seven relative clinical variables, that determine if a patient should be referred for treatment with DBS.1 The STIMULUS program was developed for use in Europe and enables neurologists to quickly and accurately determine a patient’s suitability to be considered for treatment.1()

Survey results found that of the patients examined, 70 percent fulfilled the five absolute criteria and almost two thirds of these were confirmed as eligible for DBS consideration when assessed against the relative variables. The most prevalent reasons cited for patients to not be eligible for DBS consideration were insufficiently severe motor symptoms, mental contraindications and medical conditions preventing surgery.(1)

•The STIMULUS program was developed using the scientifically validated RAND Appropriateness method (a modified Delphi method). This combines best available scientific evidence with the collective judgement of experts. DBS is considered appropriate when the expected benefits for the patient outweigh any possible negative effects by a sufficient margin that the procedure is worth doing. The STIMULUS program can be accessed online at http://test.stimulus-dbs.org.
•STIMULUS Program Screening Criteria:
Absolute CriteriaRelative Variables
Idiopathic Parkinson’s disease patientAge
Severe motor disabilityDuration of Parkinson’s disease
Insufficient response to treatment with levadopaSeverity of OFF symptoms
Not having any medical condition that prevents surgerySeverity of dyskinesias
Not having a medically resistant mental diseaseLevadopa-resistant axial symptoms
Refractory tremor
Intellectual impairment
•Deep-brain stimulation is a mild electrical stimulation in the brain which influences movement control. It is considered safe and has been shown to be well-tolerated in patients in the short and long term.9 It is an adjustable and reversible procedure that does not damage the brain tissue.10,11

•In Europe, DBS has been developed and marketed by Medtronic, Inc. under the name Activa® Therapy since 1993.

Medtronic, Inc. (www.medtronic.com - NYSE: MDT), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.

References

1.Herzog J, Allert N et al. First experiences with a decision tool to support appropriate referral for DBS in patients with Parkinson’s disease. 12 December 2007. Poster 3.206. Presented WCPD, Amsterdam.
2.De Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. “Prevalence of Parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted
3.Okun MS et al. Neurology. 2004; 63:161-163.
4.Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R et al. nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006; 21(Suppl 14): S290–304
5.European Parkinson’s Disease Association Conference. Participation in Life Survey Results 1999. Krakow, Poland. 1999. Accessed: http://www.epda.eu.com/publicationsDirectory/epdaPubArchive.shtm# 29 November 2007
6.Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355(9): 896–908
7.Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C et al. Five year follow up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Eng J Medicine. 2003; 349 (20): 1925-1934.
8.Martinez-Martin P, Deuschl G. Effect of medical and surgical interventions on health-related quality of life in Parkinson’s disease. Movement Disorders. 2007; 22(6): 757-765.
9.Halpern C, Hurtig H, Jaggi J, Grossman M, Won M, Baltuch G. Deep-brain stimulation in neurological disorders. Parkinsonism Relat Disord. 2007 13(1): 1-16.
10.NICE Guidance: Deep-brain stimulation for Parkinson’s disease. Issue date: November 2003.

11.Volkmann J, Benecke R. Deep-brain stimulation for dystonia: patient selection and evaluation. Mov Disord. 2002; 17 (Suppl 3): S112-S115.

Fiona Walton | alfa
Further information:
http://www.cohnwolfe.com
http://test.stimulus-dbs.org

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>